AbbVie Inc. $ABBV Shares Sold by BCS Wealth Management

BCS Wealth Management decreased its position in AbbVie Inc. (NYSE:ABBV) by 55.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,812 shares of the company’s stock after selling 3,557 shares during the quarter. BCS Wealth Management’s holdings in AbbVie were worth $651,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie during the second quarter worth $25,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie during the 2nd quarter worth about $36,000. Finally, Delos Wealth Advisors LLC purchased a new stake in AbbVie during the second quarter worth approximately $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $220.57 on Tuesday. The company has a market cap of $389.83 billion, a price-to-earnings ratio of 167.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.36. The company has a fifty day moving average price of $226.54 and a 200 day moving average price of $214.39. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

Wall Street Analyst Weigh In

Several equities analysts have commented on ABBV shares. UBS Group increased their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Scotiabank initiated coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Guggenheim lifted their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Finally, Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.